Table 3.

Objective responses by patients' characteristics

CovariateComplete or partial response (7/73), n (%)Stable disease (11/73), n (%)Progressive disease (55/73), n (%)P*
Age, median, y5156620.06
Gender
    Female6 (14)6 (14)31 (72)0.37
    Male1 (3.3)5 (16.7)24 (80)
Race
    Other03 (37.5)5 (62.5)0.12
    Asian2 (28.6)05 (71.4)
    Caucasian5 (8.6)8 (13.8)45 (77.6)
Smoking history
    Current smoker1 (4.2)5 (20.8)18 (75)0.12
    Former smoker2 (6.7)2 (6.7)26 (86.6)
    Never smoker4 (21.1)4 (21.1)11 (57.8)
Histology
    Adenocarcinoma7 (14.6)6 (12.5)35 (72.9)0.44
    NSCLC03 (21.4)11 (78.6)
    Squamous cell carcinoma02 (18.2)9 (81.8)
PS (ECOG)
    0-15 (12.2)8 (19.5)28 (68.3)0.37
    2-32 (6.2)3 (9.4)27 (84.4)
Stage
    IIIB02 (33.3)4 (66.7)0.31
    IV7 (10.4)9 (13.4)51 (76.2)
Previous chemotherapy regimens
    01 (9.1)1 (9.1)9 (81.8)0.67
    13 (11.5)6 (23.1)17 (65.4)
    ≥23 (8.3)4 (11.1)29 (80.6)
Pleural effusion
    No4 (9.3)6 (14)33 (76.7)0.92
    Yes3 (10)5 (16.7)22 (73.3)
Brain metastasis
    No3 (6.4)6 (12.8)38 (80.8)0.36
    Yes4 (16)4 (16)17 (68)
  • * Fisher's exact test.

  • Data retrieved at the start of gefitinib or erlotinib treatment.